Project Grant R13AG104213
- The National Institute on Aging awarded the University of Pittsburgh $190,088 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the relationship between sedentary behavior and Alzheimer's disease and related dementias. The recipient will assess how sedentary behavior relates to cognitive trajectories and biomarkers of Alzheimer's disease using data from three deeply phenotyped aging cohorts at the University of Pittsburgh alongside prospective data collection. The...
- The National Institute on Aging awarded the University of Kansas Medical Center Research Institute, Inc. $312,736 on March 1, 2026 under the Aging Research program (CFDA 93.866) to investigate the association between body composition, physical activity, and cognitive function in adults with Down syndrome. The research examines how obesity and moderate-to-vigorous physical activity relate to cognitive outcomes in adults with Down syndrome, who face approximately a 90 percent lifetime risk for...
- The National Institute on Aging awarded the Fatty Acid Research Institute $412,500 on September 1, 2026, under the Aging Research program (CFDA 93.866) to establish interaction polygenic risk scores for blood omega-3 fatty acids and genetic variants as predictors of incident all-cause dementia and Alzheimer's disease. The research identifies genetic variants that interact with blood docosahexaenoic acid (DHA) levels as risk factors for Alzheimer's disease and related dementias, with the goal...
- Grant Award Summary The National Institute on Aging awarded a $5.16 million Project Grant to the University of California, Davis on September 1, 2025, under the Aging Research program (CFDA 93.866) to investigate environmental exposures and their relationship to brain health and Alzheimer's disease and related dementias (ADRD). The project, which extends through August 31, 2029, will deliver research services examining how smartphone Global Positioning System (GPS)-based exposure data to...
- The National Institute on Aging awarded the Regents of the University of Michigan $935,722 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a randomized controlled trial of MOVE2JOY, an mHealth intervention designed to promote physical activity in middle-aged and older adults to reduce Alzheimer's disease and related dementia risk. MOVE2JOY combines two innovations: reinforcement learning algorithms that personalize intervention delivery to promote long-term...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $697,394 on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop and validate detailed quantification methods for 24-hour sleep and activity profiles from accelerometer data and to examine how modifiable activity behaviors affect Alzheimer's disease and related dementias outcomes. The project will establish approaches for robust, participant-level quantification of the full...
- The National Institute on Aging awarded the University of Memphis $146,000 on September 4, 2026, under the Aging Research program (CFDA 93.866) to investigate longitudinal patterns of multiple behavioral risk factors and their joint effects on cognitive aging. The recipient will analyze 24 years of data from the Health and Retirement Study, a nationally representative longitudinal survey of U.S. adults age 51 and older, linked with neighborhood contextual data, to examine how physical...
- The University of California, Los Angeles received a $2.7 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with completion scheduled for August 31, 2029. This research project will generate rigorous evidence comparing health outcomes for older patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) who are discharged from hospitals to home-based care versus facility-based...
- The National Institute on Aging awarded the University of Pennsylvania $687,395 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research enhancing online privacy protection and reducing scam risk for older adults with dementia and their care partners. The project investigates how people living with cognitive impairment, including mild cognitive impairment and mild-to-moderate Alzheimer's disease and related dementias, and their care partners are exposed to...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $674,088 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how environmental and psychosocial exposures shape Alzheimer's disease and related dementias outcomes. The project introduces a novel exposome-health outcomes framework tailored to real-world data, particularly Medicare...
PHYSICAL ACTIVITY AND DEMENTIA RISK - ABSTRACT PHYSICAL ACTIVITY (PA) IS AMONG THE MOST PROMISING AND SCALABLE NON-PHARMACEUTICAL STRATEGIES FOR REDUCING DEMENTIA RISK AND PRESERVING COGNITIVE FUNCTION. YET, DESPITE DECADES OF ENCOURAGING EVIDENCE, SKEPTICISM REMAINS REGARDING ITS MECHANISMS, LONG-TERM ADHERENCE, AND CONSISTENCY OF EFFECTS. FURTHER, THERE IS CURRENTLY NO DEDICATED SCIENTIFIC MEETING FOCUSED ON PA AND DEMENTIA FOR PROMOTING MEANINGFUL DIALOGUE. THIS PROPOSAL ADDRESSES THAT CRITICAL GAP BY ESTABLISHING AN ANNUAL TWO-DAY CONFERENCE "PHYSICAL ACTIVITY AND DEMENTIA RISK" DESIGNED TO UNITE FRAGMENTED EFFORTS, FOSTER INTERNATIONAL COLLABORATION, AND ACCELERATE PROGRESS IN THE FIELD. THE MEETING WILL CONVENE RESEARCHERS, CLINICIANS, TRAINEES, AND POLICYMAKERS TO ADDRESS UNRESOLVED QUESTIONS: DOES REVERSE CAUSALITY EXPLAIN RESULTS FROM OBSERVATIONAL PA STUDIES? WHY DO RANDOMIZED CLINICAL TRIALS (RCTS) OF PA YIELD INCONSISTENT BRAIN HEALTH RESULTS? HOW CAN WE IMPROVE PA IMPLEMENTATION AND ENGAGEMENT, ESPECIALLY IN AT-RISK POPULATIONS? WHAT ARE THE MECHANISMS UNDERLYING THE BENEFICIAL EFFECTS OF PA ON BRAIN HEALTH? CAN PA BE COMBINED WITH OTHER THERAPIES FOR ADDED BENEFITS? AND HOW DO WE EXPLAIN INDIVIDUAL VARIABILITY IN RESPONSE TO PA? THE CONFERENCE WILL FEATURE PRESENTATIONS BY LEADING INTERNATIONAL EXPERTS ACROSS DISCIPLINES, COVERING BASIC BIOLOGICAL MECHANISMS AND ANIMAL MODELS, EPIDEMIOLOGICAL RESEARCH, INTERVENTION STUDIES, IMPLEMENTATION SCIENCE, AND PERSONALIZED APPROACHES. WE WILL BRING TOGETHER INVESTIGATORS ACROSS DISCIPLINES AND CAREER STAGES SO THAT THE MEETING WILL SERVE AS A CATALYST FOR SCIENTIFIC PROGRESS AND CROSS-SECTOR DIALOGUE. THE PROGRAM WILL EMPHASIZE HARMONIZATION OF METHODS, CROSS-STUDY COMPARISONS, AND CONSENSUS- BUILDING TO ADVANCE RESEARCH AND INFORM PRACTICE. THEMATIC SESSIONS WILL SPAN METHODOLOGICAL AND ANALYTICAL INNOVATIONS FOR MEASURING PA, SEDENTARY BEHAVIOR, AND CARDIORESPIRATORY FITNESS, ALONGSIDE AN EXAMINATION OF HOW PA MIGHT INFLUENCE ALZHEIMER'S DISEASE BIOMARKERS (E.G., PTAU217) AND OTHER INDICATORS OF DEMENTIA RISK (E.G., NEUROIMAGING METRICS). IMPORTANTLY, THE SCOPE OF THE CONFERENCE WILL INCLUDE MULTIPLE FORMS OF DEMENTIA - ALZHEIMER'S DISEASE, VASCULAR DEMENTIA, FRONTOTEMPORAL DEMENTIA, LEWY BODY DEMENTIA, AND PARKINSON'S DISEASE DEMENTIA - WHILE ADDRESSING THE COMPLEXITY OF MIXED PATHOLOGIES AND FREQUENT COMORBIDITIES. WE WILL PROMOTE IN-DEPTH DISCUSSIONS ON POTENTIAL CONFOUNDING AND CONFLATING FACTORS FOR THE EFFECTS OF PA, AS WELL AS MODERATORS AND MEDIATORS OF THE ASSOCIATIONS WITH DEMENTIA RISK-SUCH AS TYPE 2 DIABETES, CARDIOVASCULAR HEALTH, AND RELATED SYSTEMIC CONDITIONS. BY ESTABLISHING A DEDICATED FORUM, THIS MEETING AIMS TO CATALYZE DISCOVERY, IMPROVE TRANSLATION, AND SHARE RESULTS LINKING PA ITO BRAIN HEALTH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $50.0k | 8/19/26 |